Christopher M. Walthers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christopher M. Walthers has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Amr Almaktari
Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California
27 shared publications - Antoni Ribas
Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, USA
27 shared publications - Beata Berent-Maoz
Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California
27 shared publications - Brenda Ji
Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California
27 shared publications - Caitlin Harris
University of California, Los Angeles 3 Department of Microbiology, Immunology, and Molecular Genetics Los Angeles, CA, USA
27 shared publications - Caspian Oliai
UCLA Medical Center 6 Los Angeles, CA
27 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
CD14/CD20 depletion did not significantly alter regulatory T (Treg) cell content in CART19/20 cell product and in patient peripheral blood post infusion. Intracellular staining of starting (unactivated) TN/MEM population, CART19/20 final product, and patient PBMC collected 14 days post CART19/20 infusion. FOXP3+ frequency is shown as a percentage of CD3+CD4+ T cells.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
CD14/CD20 depletion did not significantly alter regulatory T (Treg) cell content in CART19/20 cell product and in patient peripheral blood post infusion. Intracellular staining of starting (unactivated) TN/MEM population, CART19/20 final product, and patient PBMC collected 14 days post CART19/20 infusion. FOXP3+ frequency is shown as a percentage of CD3+CD4+ T cells.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
T cell populations become CD8-dominant post CART19/20 cell infusion. % CD8+ among (A) CAR-expressing T cells and (B) all CD3+ T cells was quantified by flow cytometry. Data are shown for CAR-T cells only up to day 90 post infusion as values post day 90 become unreliable due to low CAR+ cell count detected by flow. FP: final product (i.e., cryopreserved CART19/20 cells).
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
T cell populations become CD8-dominant post CART19/20 cell infusion. % CD8+ among (A) CAR-expressing T cells and (B) all CD3+ T cells was quantified by flow cytometry. Data are shown for CAR-T cells only up to day 90 post infusion as values post day 90 become unreliable due to low CAR+ cell count detected by flow. FP: final product (i.e., cryopreserved CART19/20 cells).
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
PET scans taken for all patients treated with CART19/20 cell therapy.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
PET scans taken for all patients treated with CART19/20 cell therapy.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Flow-cytometry analysis of post-infusion peripheral blood samples. (A) Gating strategy for T-cell analysis in CART19/20 cell products and post-infusion patient peripheral mononuclear blood cells (PBMCs). Two viable gates were set based on side scatter (SSC-A) vs. forward scatter (FSC-A). The more restrictive “Viable” gate includes only viable lymphocytes, to enable more precise identification of T cells. The “Viable (inclusive)” gate includes all viable PBMCs, to enable calculation of CAR-T cells as a fraction of PBMCs. Truncated epidermal growth factor receptor (EGFRt) is co-expressed with the CAR, and EGFRt staining is used for CAR expression detection. Percent CAR+ T cells among viable singlets as shown in main-text Fig. 4b is the EGFRt+ population as a % of grandparent in the viable PBMC branch.Percent CAR expression among T cells as shown in main-text Fig. 4c is the EGFRt+ population as a % of parent in the viable lymphocyte branch. (B) Examples of post-infusion patient sample analysis.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Flow-cytometry analysis of post-infusion peripheral blood samples. (A) Gating strategy for T-cell analysis in CART19/20 cell products and post-infusion patient peripheral mononuclear blood cells (PBMCs). Two viable gates were set based on side scatter (SSC-A) vs. forward scatter (FSC-A). The more restrictive “Viable” gate includes only viable lymphocytes, to enable more precise identification of T cells. The “Viable (inclusive)” gate includes all viable PBMCs, to enable calculation of CAR-T cells as a fraction of PBMCs. Truncated epidermal growth factor receptor (EGFRt) is co-expressed with the CAR, and EGFRt staining is used for CAR expression detection. Percent CAR+ T cells among viable singlets as shown in main-text Fig. 4b is the EGFRt+ population as a % of grandparent in the viable PBMC branch.Percent CAR expression among T cells as shown in main-text Fig. 4c is the EGFRt+ population as a % of parent in the viable lymphocyte branch. (B) Examples of post-infusion patient sample analysis.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
CART19/20 cell product characteristics. (A) % CD4+ among total T cells and CAR-expressing T cells. (B) Comparison of T-cell subtype frequency among CD4+ vs. CD8+ T cells in cryopreserved CART19/20 cell products. Te/exh: effector/exhausted T cells, CD45RA+/CD45RO–/CD62L–; Tem: effector-memory T cells, CD45RA–/CD45RO+/CD62L–; Tcm: central-memory T cells: CD45RA–/CD45RO+/CD62L+; naïve: CD45RA+/CD45RO–/CD62L+. (C) Phenotype of leukopak content prior to cell isolation. (D) Phenotype of cells obtained after isolation. (E) CD14 and CD25 expression patterns among CD62L+ cells in patient leukopak content prior to cell isolation.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
CART19/20 cell product characteristics. (A) % CD4+ among total T cells and CAR-expressing T cells. (B) Comparison of T-cell subtype frequency among CD4+ vs. CD8+ T cells in cryopreserved CART19/20 cell products. Te/exh: effector/exhausted T cells, CD45RA+/CD45RO–/CD62L–; Tem: effector-memory T cells, CD45RA–/CD45RO+/CD62L–; Tcm: central-memory T cells: CD45RA–/CD45RO+/CD62L+; naïve: CD45RA+/CD45RO–/CD62L+. (C) Phenotype of leukopak content prior to cell isolation. (D) Phenotype of cells obtained after isolation. (E) CD14 and CD25 expression patterns among CD62L+ cells in patient leukopak content prior to cell isolation.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Comparison of CART19/20 cell therapy results with reported data from trials evaluating other CD19/CD20 bispecific CAR-T cell therapies and commercially available CD19 CAR-T cell therapies.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Comparison of CART19/20 cell therapy results with reported data from trials evaluating other CD19/CD20 bispecific CAR-T cell therapies and commercially available CD19 CAR-T cell therapies.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Representativeness of study participants
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Representativeness of study participants
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Patient 009 exhibited elevated cytokine, C-reactive protein, and ferritin levels prior to and after CART19/20 cell infusion. (A) Serum levels of various cytokines measured by Luminex multiplex assay. (B) C-reactive protein (CRP) levels for Patient 009 (left-most) and all patients (second from left). Peak and median CRP levels are shown in box-and-whisker plots. (C) Ferritin levels for Patient 009 (left-most) and all patients (second from left). Peak and median ferritin levels are shown in box-and-whisker plots.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Patient 009 exhibited elevated cytokine, C-reactive protein, and ferritin levels prior to and after CART19/20 cell infusion. (A) Serum levels of various cytokines measured by Luminex multiplex assay. (B) C-reactive protein (CRP) levels for Patient 009 (left-most) and all patients (second from left). Peak and median CRP levels are shown in box-and-whisker plots. (C) Ferritin levels for Patient 009 (left-most) and all patients (second from left). Peak and median ferritin levels are shown in box-and-whisker plots.